UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 131

Sortiert nach

Liver stiffness in the hepatitis B virus carrier： A non-invasive marker of liver disease influenced by the pattern of transaminases

World journal of gastroenterology : WJG, 2008-10, Vol.14 (40), p.6154-6162

2008

Link zum Volltext

Verfügbarkeit prüfen

Editorial: which factors influence HBsAg levels in HBV‐infected patients? Authors' reply

Alimentary pharmacology & therapeutics, 2020-08, Vol.52 (3), p.549-550

2020

Link zum Volltext

Verfügbarkeit prüfen

Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease

Diabetes/metabolism research and reviews, 2024-02, Vol.40 (2), p.e3736-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)

Liver international, 2021-08, Vol.41 (8), p.1713-1733

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

The New England journal of medicine, 2023-07, Vol.389 (1), p.22-32

2023

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B Virus Surface Antigen Levels : A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B

Hepatology (Baltimore, Md.), 2009-04, Vol.49 (4), p.1141-1150

2009

Link zum Volltext

Verfügbarkeit prüfen

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

PloS one, 2015-06, Vol.10 (6), p.e0130209-e0130209

2015

Link zum Volltext

Verfügbarkeit prüfen

Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis

World journal of gastroenterology : WJG, 2009-02, Vol.15 (5), p.531-537

2009

Link zum Volltext

Verfügbarkeit prüfen

The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage

International journal of molecular sciences, 2022-07, Vol.23 (13), p.7447

2022

Link zum Volltext

Verfügbarkeit prüfen

Interferon Therapy of Chronic Hepatitis B

Intervirology, 2014-01, Vol.57 (3-4), p.163-170

2014

Link zum Volltext

Verfügbarkeit prüfen

A “systems medicine” approach to the study of non-alcoholic fatty liver disease

Digestive and liver disease, 2016-03, Vol.48 (3), p.333-342

2016

Link zum Volltext

Verfügbarkeit prüfen

Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut–Liver Inflammation: A Study with Positron Emission Tomography and Oral 18FDG in Mice

International journal of molecular sciences, 2022-02, Vol.23 (5), p.2659

2022

Link zum Volltext

Verfügbarkeit prüfen

Urgent Liver Transplantation Soon After Recovery From COVID‐19 in a Patient With Decompensated Liver Cirrhosis

Hepatology communications, 2021-01, Vol.5 (1), p.144-145

2021

Link zum Volltext

Verfügbarkeit prüfen

Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet

Nutrients, 2021-09, Vol.13 (10), p.3438

2021

Link zum Volltext

Verfügbarkeit prüfen

The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection

Viruses, 2023-11, Vol.15 (11), p.2257

2023

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach

Pharmaceuticals (Basel, Switzerland), 2021-09, Vol.14 (10), p.995

2021

Link zum Volltext

Verfügbarkeit prüfen

A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection

PloS one, 2014-10, Vol.9 (10), p.e110782-e110782

2014

Link zum Volltext

Verfügbarkeit prüfen

Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort

Hepatology (Baltimore, Md.), 2017-12, Vol.66 (6), p.1814-1825

2017

Link zum Volltext

Verfügbarkeit prüfen

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

PloS one, 2017-10, Vol.12 (10), p.e0185728-e0185728

2017

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Utility of the Saliva Proteome in Rare Diseases: A Pilot Study for Biomarker Discovery in Primary Sclerosing Cholangitis

Journal of clinical medicine, 2024-01, Vol.13 (2), p.544

2024

Link zum Volltext

Verfügbarkeit prüfen

Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis

Healthcare (Basel), 2022-02, Vol.10 (2), p.374

2022

Link zum Volltext

Verfügbarkeit prüfen

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study

Frontiers in pharmacology, 2022-05, Vol.13, p.869842-869842

2022

Link zum Volltext

Verfügbarkeit prüfen

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

Journal of hepatology, 2012-06, Vol.56 (6), p.1254-1258

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 131

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(113)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Hepatology
(20)
Digestive And Liver Disease
(13)
Gastroenterology
(9)
Hepatology
(8)
Plos One
(6)
Cancers
(4)
Liver
(4)
World Journal Of Gastroenterology : Wjg
(4)
International Journal Of Molecular Sciences
(3)
Journal Of Clinical Medicine
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Liver stiffness in the hepatitis B virus carrier： A non-invasive marker of liver disease influenced by the pattern of transaminases

Editorial: which factors influence HBsAg levels in HBV‐infected patients? Authors' reply

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease

Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Hepatitis B Virus Surface Antigen Levels : A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis

The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage

Interferon Therapy of Chronic Hepatitis B

A “systems medicine” approach to the study of non-alcoholic fatty liver disease

Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut–Liver Inflammation: A Study with Positron Emission Tomography and Oral 18FDG in Mice

Urgent Liver Transplantation Soon After Recovery From COVID‐19 in a Patient With Decompensated Liver Cirrhosis

Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet

The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection

Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach

A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection

Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

The Clinical Utility of the Saliva Proteome in Rare Diseases: A Pilot Study for Biomarker Discovery in Primary Sclerosing Cholangitis

Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

Suchergebnisse filtern